Updates On Xarelto Lawsuit News

March 02, 2017 – – Drug-Lawsuits.org is a website dedicated to providing Xarelto lawsuit news to consumers. The site has recently announced that there are updates available for those who are considering or who have already filed a lawsuit. Xarelto is an anticoagulant that was approved for sale in November 2012 by the FDA. Since that time, numerous patients have come forward with reports of potentially serious side effects caused by the drug.

By early 2003, less than a full year after the drug was approved for sale, the FDA had received more than 2,000 reports of serious side effects caused by the medication. By the drug’s first year on the market, there were more than 150 deaths reported, all of which were allegedly directly related to the drug. In January 2014, the FDA issued a statement saying that the drug posed a serious issue for those taking it.

“The FDA’s warning stated that there could be significant blood loss in patients who took Xarelto,” says a spokesperson for Drug-Lawsuits.org. “The warning recommended that those who had taken the drug and who were seeing symptoms of blood loss have a blood replacement or transfusion. That’s how serious this issue was and continues to be.”

One of the main factors in the lawsuit is Janssen Pharmaceutical, the manufacturer of the drug, and the fact that they do not provide a reversal agent or antidote. “Similar claims were filed over Pradaxa,” says the spokesperson. “Pradaxa was introduced just before Xarelto and there are now more than 4,000 plaintiffs who state that they are experiencing bleeding injuries.” Pradaxa lawsuits were in litigation for several years, and the manufacturer agreed to pay a $650 million settlement, which averaged out at approximately $150,000 for each claim.

Experts state that Xarelto plaintiffs could see a similar claim settlement, and say that the number of lawsuits continues to increase. Drug-Lawsuits.org continues to provide consumers with information on these lawsuits, including the upcoming bellwether trials, which are set to begin in Louisiana in April 2017. Those interested in getting more information can visit the website to learn about current and pending litigation against Janssen Pharmaceuticals and its subsidiary Johnson & Johnson.

###

Contact Drug-Lawsuits.org:

info@drug-lawsuits.org

ReleaseID: 60015233